title: Induction chemotherapy with paclitaxel and cisplatin and CT-based 3D radiotherapy in patients with advanced laryngeal and hypopharyngeal carcinomas--a possibility for organ preservation.
abstract: BACKGROUND
  To evaluate the effect of paclitaxel/cisplatin induction chemotherapy (ICHT) and CT-based radiotherapy (RT) on larynx preservation, tumor control, and survival in patients with larynx/hypopharynx carcinoma eligible for total laryngectomy (TL) or TL plus partial pharyngectomy (TLPP).
  
  
  METHODS
  Fifty patients eligible for TL or TLPP were enrolled onto a prospective study and treated with ICHT (200 mg/m(2) paclitaxel, 100 mg/m(2) cisplatin; day 1, 22). In patients with complete or partial tumor response RT (69.9 Gy in 5.5 weeks at the gross tumor, 50.4 Gy in the lymphatic drainage; single dose: 1.8 Gy, concomitant boost: 1.5 Gy) was applied. Non-responders had TL/TLPP and RT with total doses adapted to the radicality of tumor resection (56-70 Gy).
  
  
  RESULTS
  The response rate to ICHT was 88% (10% complete, 78% partial response). At a median follow-up period of 25 months the larynx preservation rate was 84%. The 2-year local-regional control rate was 91% and the 2-year overall survival rate was 72.3%. The 3-year estimate to survive with functional larynx is 60%.
  
  
  CONCLUSIONS
  In a large portion of patients eligible for TL or TLPP the larynx was preserved by paclitaxel/cisplatin ICHT and 3D RT.
authors.affiliation: Department of Radiation Oncology, University of Wuerzburg, Josef-Schneider-Str.11, 97080 Wuerzburg, Germany. pfreundner@strahlentherapie.uni-wuerzburg.de
authors.forename: Leo
authors.initials: L
authors.lastname: Pfreundner
authors.forename: Florian
authors.initials: F
authors.lastname: Hoppe
authors.forename: Jochen
authors.initials: J
authors.lastname: Willner
authors.forename: Verena
authors.initials: V
authors.lastname: Preisler
authors.forename: Klaus
authors.initials: K
authors.lastname: Bratengeier
authors.forename: Rudolf
authors.initials: R
authors.lastname: Hagen
authors.forename: Jan
authors.initials: J
authors.lastname: Helms
authors.forename: Michael
authors.initials: M
authors.lastname: Flentje
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002277:Carcinoma / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000532:radiotherapy*; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D007012:Hypopharyngeal Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000532:radiotherapy*; D021621:Imaging, Three-Dimensional; D007822:Laryngeal Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000532:radiotherapy*; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D020360:Neoadjuvant Therapy; D009364:Neoplasm Recurrence, Local; D017239:Paclitaxel / Q000008:administration & dosage; D011446:Prospective Studies; D011832:Radiation Injuries; D014057:Tomography, X-Ray Computed
chemical_list: D017239:Paclitaxel; D002945:Cisplatin